DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for ovarian epithelial tumor — screening already-approved drugs against its 40-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian epithelial tumor maps to a 40-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian epithelial tumor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tenascin C (TNC) — TNC is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3-methyl-1,2,4-thiadiazol-5-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5R61 · 1.38 Å · ligand 1-(3-methyl-1,2,4-thiadiazol-5-yl)-1,4-diazepane (K1P). Experimental structure, not a prediction.
What the evidence adds up to
Epithelial ovarian cancer is typically diagnosed at an advanced stage, and despite initial treatment with surgical resection and platinum/taxane-based chemotherapy, over 70–80% of patients achieve remission but a significant proportion later develop recurrence. The disease remains largely lethal because of late-stage diagnosis and the eventual development of chemotherapy resistance. Most women who recur require multiple further therapies, and additional cytotoxic chemotherapy plus surgery is the standard approach for managing recurrent disease.
Several review articles published between 2005 and 2023 describe the same pattern: current management relies on surgery for early-stage cancer and chemotherapy combinations for advanced-stage disease. No abstract reports a specific survival or response rate from any novel therapy. One 2012 review notes that therapies targeting specific molecular pathways are rapidly developing in the laboratory and increasingly being studied in patients, but provides no concrete efficacy data. A 2023 review states that gene therapy and stem cell therapy are the cornerstones of current investigation, with a particular focus on local treatment, but again gives no numerical outcomes.
Immunohistochemistry and molecular testing have helped pathologists recognise the significant heterogeneity of epithelial ovarian carcinomas, and this molecular understanding is described as a first step toward developing targeted therapies. However, across all five abstracts, no drug, targeted agent, or repurposed compound is named, and no trial results are reported. The literature reviewed here is entirely descriptive and programmatic.
What is still missing are completed clinical trials that report response rates, progression-free survival, or overall survival for any specific novel therapy in epithelial ovarian cancer. The abstracts do not provide data on patient stratification by molecular subtype, nor do they describe funding for the necessary phase II or III studies. Without such evidence, the repeated calls for novel therapies remain aspirational.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
癌症：英文版 · 2015 · 75 citations · open access
Pathobiology of ovarian carcinomas
AbstractOvarian tumors comprise a heterogeneous group of lesions, displaying distinct tumor pathology and oncogenic potentiel. These tumors are subdivided into three main categories: epithelial, germ cell, and sex-cord stromal tumors. We report herein the newly described molecular abnormalities in epithelial ovarian cancers (carcinomas). Immunohistochemistry and molecular testing help pathologists to decipher the significant heterogeneity of this disease. Our better understanding of the molecular basis of ovarian carcinomas represents the first step in the development of targeted therapies in the near future.
AbstractOvarian cancer is a malignant disease that affects thousands of patients every year. Currently, we use surgical techniques for early-stage cancer and chemotherapy treatment combinations for advanced stage cancer. Several novel therapies are currently being investigated, with gene therapy and stem cell therapy being the corner stone of this investigation. We conducted a thorough search on PubMed and gathered up-to-date information regarding epithelial ovarian cancer therapies. We present, in the current review, all novel treatments that were investigated in this field over the past five years, with a particular focus on local treatment.
Expert Opinion on Pharmacotherapy · 2007 · 25 citations
Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics
AbstractEpithelial ovarian cancer will strike between 1 - 2% of women in developed countries and, unfortunately, it largely remains a lethal disease due to late-stage at diagnosis and the eventual development of chemotherapy resistance. Ovarian cancer is initially treated with surgical resection and chemotherapy (primarily platinum/taxane combinations) and remission can be attained for the majority of patients. Despite this, most women will recur and require multiple further therapies. The purpose of this paper is to review the existing treatment options, including surgery, traditional chemotherapy as well as upcoming novel and targeted therapies that may one day improve outcomes in this disease.
Clinical utility of targeted treatments in the management of epithelial ovarian cancer
AbstractEpithelial ovarian cancer is typically found in its advanced stages, where a combination of surgical debulking and platinum/taxane-based chemotherapy is recommended. Although over 70%-80% of patients achieve remission, a significant proportion develop recurrence of their disease. Additional cytotoxic chemotherapy, as well as surgery, is typically used to manage disease recurrence. Therapies that target specific pathways in cancer cells are rapidly developing in the laboratory and are increasingly being studied in patients with ovarian cancer. We review the current status of novel therapies in the management of epithelial ovarian cancer.
AbstractEpithelial ovarian cancer is a common gynecologic malignancy with an increasing incidence possibly due to the spread of ‘Westernized’ lifestyles. Currently most women present at an advanced stage, and despite radical surgery and chemotherapy, will eventually die from their disease. This article aims to review current surgical and medical management of women with ovarian cancer and the evidence which supports it. Finally, there will be a brief discussion of some of the novel therapies in development.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
